Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Liu Joy

McKechnie Duncan

Kewalramani Reshma

Bozic Carmen

Vertex Pharmaceuticals has been a strong long-term performer but faces challenges with slowing growth in its core cystic fibrosis business and struggles diversifying into new markets. However, the company shows promise with upcoming approvals for gene-editing therapy Casgevy and kidney disease treatment povetacicept, which could drive future growth and make it attractive at current levels.

Is This Millionaire-Maker Biotech Stock a Buy Right Now?

The article analyzes two underperforming healthcare stocks as potential buying opportunities: Intuitive Surgical and Vertex Pharmaceuticals. Despite recent headwinds including tariffs, increased competition, and portfolio diversification challenges, both companies have strong long-term prospects. Intuitive Surgical maintains leadership in robotic-assisted surgery with a vast addressable market, while Vertex Pharmaceuticals has a stable cystic fibrosis business and promising pipeline candidates. Both stocks are trading around $425-$460, allowing investors to purchase two shares with $1,000.

Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?

I teach traders how to spot strength early and trade it with conviction | Head of TA @ Stock Talk Insiders | TEL Newsletter https://t.co/dgkZrWtRFE

Danny Naz

All stocks and economy. All the time. Except when I mix in references to sports and pop culture. Senior markets analysis writer @barronsonline. Ex-@CNNBusiness.

Vertex Pharmaceuticals Inc (VRTX) Stock Price, Analysis & Trade Signals